Valuation: Entrada Therapeutics, Inc.

Market Cap 238M 209M 193M 178M 336M 22.76B 343M 2.3B 903M 11.18B 893M 874M 38.6B P/E 2026 *
-1.63x
P/E 2027 * -1.74x
Enterprise Value 144M 127M 117M 108M 204M 13.81B 208M 1.4B 548M 6.78B 542M 530M 23.43B EV / Sales 2026 *
9.63x
EV / Sales 2027 * -3.14x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day-4.62%
1 week-12.35%
Current month-10.33%
1 month+2.17%
3 months-52.48%
6 months-36.90%
Current year-35.80%
1 week 6.51
Extreme 6.51
7.5
1 month 6.35
Extreme 6.35
8.1
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 2017-07-31
Director of Finance/CFO 47 2020-10-31
President 56 2023-12-31
Director TitleAgeSince
Director/Board Member 67 2020-11-30
Director/Board Member 66 2021-05-03
Director/Board Member 59 2023-08-31
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Director

19,000 0.0489%
06-09Free

Director

19,000 0.0489%
06-09Free

Chairman

19,000 0.0489%
Change 5-day change 1-year change 3-year change Capi.($)
-4.62%-12.35%+0.76%-59.16% 238M
-2.48%-2.22%+55.85%+79.12% 53.54B
-0.34%-6.75%+55.40%+126.77% 54.18B
-5.60%-2.15%+11.16%+420.46% 23.66B
-1.55%-4.11%-20.21%-17.75% 22.78B
+2.36%+3.86%+42.80%-6.60% 19.54B
-0.76%-0.21%+37.94%-27.90% 17.82B
-2.72%-4.04%+187.08%+362.09% 16.01B
-1.15%-3.07%+45.33%+654.85% 15.37B
-0.81%+0.92%+24.92%+189.61% 14.09B
Average -1.76%-2.75%+44.10%+172.15% 23.72B
Weighted average by Cap. -1.51%-2.00%+47.85%+162.46%

Financials

2026 *2027 *
Net sales 14.99M 13.15M 12.18M 11.2M 21.19M 1.43B 21.6M 145M 56.92M 705M 56.29M 55.06M 2.43B 29.81M 26.15M 24.22M 22.28M 42.14M 2.85B 42.96M 289M 113M 1.4B 112M 109M 4.84B
Net income -176M -154M -143M -131M -249M -16.83B -253M -1.7B -668M -8.26B -660M -646M -28.54B -188M -165M -152M -140M -265M -17.95B -270M -1.82B -712M -8.82B -704M -689M -30.45B
Net Debt -93.49M -82M -75.95M -69.88M -132M -8.95B -135M -905M -355M -4.39B -351M -343M -15.18B -331M -291M -269M -248M -469M -31.72B -478M -3.21B -1.26B -15.58B -1.24B -1.22B -53.8B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
26-07-13 US$6.600 -4.62% 284,674
26-07-10 US$6.920 -6.49% 380,492
26-07-09 US$7.400 +1.09% 603,163
26-07-08 US$7.320 -1.74% 541,144
26-07-07 US$7.450 -1.06% 374,539
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.600USD
Average target price
18.75USD
Spread / Average Target
+184.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock